Reports Q4 revenue $28.58M , consensus $27.43M.”We are very thankful to all our partner doctors and practices for joining with the RxSight team to consistently deliver high-quality vision across a range of distances,” said Ron Kurtz, CEO and President of RxSight. “As we step into 2024, we aim to expand our ability to optimize premium cataract surgery by unlocking the full potential of adjustable technology for patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RXST:
- RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
- RxSight price target raised to $61 from $43 at BTIG
- RxSight, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- RxSight price target raised to $54 from $45 at Stifel
- RxSight price target raised to $41 from $35 at Needham